Allogene Therapeutics Inc (NASDAQ:ALLO) has a beta value of 0.84 and has seen 0.43 million shares traded in the recent trading session. The company, currently valued at $441.36M, closed the recent trade at $2.11 per share which meant it lost -$0.07 on the day or -3.44% during that session. The ALLO stock price is -173.93% off its 52-week high price of $5.78 and 37.44% above the 52-week low of $1.32.
The consensus among analysts is that Allogene Therapeutics Inc (ALLO) is Buy stock at the moment, with a recommendation rating of 1.56. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 6 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.32.
Allogene Therapeutics Inc (NASDAQ:ALLO) trade information
Sporting -3.44% in the red today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ALLO stock price touched $2.11 or saw a rise of 9.05%. Year-to-date, Allogene Therapeutics Inc shares have moved -1.17%, while the 5-day performance has seen it change 16.94%. Over the past 30 days, the shares of Allogene Therapeutics Inc (NASDAQ:ALLO) have changed 31.56%.
Wall Street analysts have a consensus price target for the stock at $33.5, which means that the shares’ value could jump 93.7% from the levels at last check today. The projected low price target is $7.0 while the price target rests at a high of $55.0. In that case, then, we find that the latest price level in today’s session is -2506.64% off the targeted high while a plunge would see the stock gain -231.75% from the levels at last check today.
Allogene Therapeutics Inc (ALLO) estimates and forecasts
The company’s shares have lost -16.14% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -66.32%.
15 analysts offering their estimates for the company have set an average revenue estimate of 11.2k for the current quarter. 11 have an estimated revenue figure of 4.55k for the next ending quarter. Year-ago sales stood 21k and 22k respectively for this quarter and the next, and analysts expect sales will shrink by -46.67% for the current quarter and -66.32% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 22.18% over the past 5 years. Earnings growth for 2025 is a modest 36.25% while over the next 5 years, the company’s earnings are expected to increase by 11.41%.
ALLO Dividends
Allogene Therapeutics Inc is expected to release its next earnings report in April this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Allogene Therapeutics Inc (NASDAQ:ALLO)’s Major holders
The top two institutional holders are FMR LLC with over 31.26 million shares worth more than $72.83 million. As of 2024-06-30, FMR LLC held 16.4491% of shares outstanding.
The other major institutional holder is TPG GP A, LLC, with the holding of over 18.72 million shares as of 2024-06-30. The firm’s total holdings are worth over $43.61 million and represent 9.8493% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Smallcap World Fund and Fidelity Select Portfolios – Health Care. As of Dec 31, 2024, the former fund manager holds about 3.29% shares in the company for having 6.9 shares of worth $14.48 million while later fund manager owns 4.35 shares of worth $9.13 million as of Dec 31, 2024, which makes it owner of about 2.07% of company’s outstanding stock.
